Send to

Choose Destination
J Labelled Comp Radiopharm. 2018 Jul;61(9):672-692. doi: 10.1002/jlcr.3628. Epub 2018 May 14.

Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Author information

Department of Chemistry, Hunter College of the City University of New York, New York, New York, USA.
Department of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Radiology, Weill Cornell Medical College, New York, New York, USA.


Over the past 25 years, antibodies have emerged as extraordinarily promising vectors for the delivery of radionuclides to tumors for nuclear imaging. While radioimmunoconjugates often produce very high activity concentrations in target tissues, they also are frequently characterized by elevated activity concentrations in healthy organs as well. The root of this background uptake lies in the complex network of biological interactions between the radioimmunoconjugate and the subject. In this review, we seek to provide an overview of these interactions and thus paint a general picture of the in vivo fate of radioimmunoconjugates. To cover the entire story, we have divided our discussion into 2 parts. First, we will address the path of the entire radioimmunoconjugate as it travels through the body. And second, we will cover the fate of the radionuclide itself, as its course can diverge from the antibody under certain circumstances. Ultimately, our goal is to provide the nuclear imaging field with a resource covering these important-yet often underestimated-pathways.


FcRn; PET; SPECT; antibodies; copper-64; immunoPET; immunoSPECT; indium-111; monoclonal antibodies; pharmacodynamics; pharmacokinetics; positron emission tomography; radioimmunoconjugates; radioiodine; radiometals; single photon emission computed tomography; zirconium-89

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center